Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Palliative Liver Radiotherapy (RT) for Symptomatic Hepatocellular Carcinoma (HCC).
Scientific Reports ( IF 3.8 ) Pub Date : 2020-01-27 , DOI: 10.1038/s41598-020-58108-1 Cynthia S Y Yeung 1 , C L Chiang 1, 2, 3 , Natalie S M Wong 1 , S K Ha 2 , K S Tsang 2 , Connie H M Ho 1 , B Wang 3 , Venus W Y Lee 1 , Mark K H Chan 4 , Francis A S Lee 1
Scientific Reports ( IF 3.8 ) Pub Date : 2020-01-27 , DOI: 10.1038/s41598-020-58108-1 Cynthia S Y Yeung 1 , C L Chiang 1, 2, 3 , Natalie S M Wong 1 , S K Ha 2 , K S Tsang 2 , Connie H M Ho 1 , B Wang 3 , Venus W Y Lee 1 , Mark K H Chan 4 , Francis A S Lee 1
Affiliation
|
This study aims at evaluating the symptom response, response duration, and toxicity of single dose palliative liver radiotherapy (RT) for symptomatic HCC patients. We reviewed unresectable HCC patients treated with palliative RT in our institution. Eligible patients were unsuitable or refractory to trans-arterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT), with an index symptom of pain or abdominal discomfort. The primary outcome was the percentage of patients with clinical improvement of index symptom at 1 month. Secondary outcomes were response duration, toxicities, alpha-feto protein (AFP) response, and radiological response. Fifty-two patients were included in the study. The index symptom was pain in 34 patients (65.4%), and abdominal discomfort (34.6%) in 18 patients. At 1 month, 51.9% of patients had improvement of symptoms. Median time to symptom progression was 89 days (range: 12-392 days). Treatment was well tolerated with only 2 patients (3.8%) developing grade 3 GI toxicities. AFP response, radiological response rate, and disease control rate at 3 months were 48.6%, 15.1%, and 54.5% respectively. Half of the patients had improvement of index symptoms after receiving palliative liver RT with median response duration of 3 months. The treatment was well tolerated with minimal toxicities.
中文翻译：
有症状的肝细胞癌（HCC）的姑息性肝放射疗法（RT）。
本研究旨在评估有症状的HCC患者的单剂量姑息性肝放疗（RT）的症状反应，反应持续时间和毒性。我们回顾了在我们机构中接受姑息性RT治疗的无法切除的HCC患者。符合条件的患者不适合或难于经动脉化学栓塞（TACE）和立体定向身体放疗（SBRT），并伴有疼痛或腹部不适的症状。主要结局是1个月时临床症状改善的患者百分比。次要结果是反应持续时间，毒性，甲胎蛋白（AFP）反应和放射学反应。该研究包括52名患者。指数症状为疼痛34例（65.4％），腹部不适（34.6％）18例。在1个月时，为51。9％的患者症状有所改善。症状发展的中位时间为89天（范围：12-392天）。只有2名患者（3.8％）出现3级GI毒性，治疗耐受性良好。3个月时AFP反应，放射反应率和疾病控制率分别为48.6％，15.1％和54.5％。一半患者接受姑息性肝放疗后症状症状有所改善，中位反应持续时间为3个月。该治疗耐受性良好，毒性最小。一半患者接受姑息性肝放疗后症状症状有所改善，中位反应持续时间为3个月。该治疗耐受性良好，毒性最小。一半患者接受姑息性肝放疗后症状症状有所改善，中位反应持续时间为3个月。该治疗耐受性良好，毒性最小。
更新日期：2020-01-27
中文翻译：
有症状的肝细胞癌（HCC）的姑息性肝放射疗法（RT）。
本研究旨在评估有症状的HCC患者的单剂量姑息性肝放疗（RT）的症状反应，反应持续时间和毒性。我们回顾了在我们机构中接受姑息性RT治疗的无法切除的HCC患者。符合条件的患者不适合或难于经动脉化学栓塞（TACE）和立体定向身体放疗（SBRT），并伴有疼痛或腹部不适的症状。主要结局是1个月时临床症状改善的患者百分比。次要结果是反应持续时间，毒性，甲胎蛋白（AFP）反应和放射学反应。该研究包括52名患者。指数症状为疼痛34例（65.4％），腹部不适（34.6％）18例。在1个月时，为51。9％的患者症状有所改善。症状发展的中位时间为89天（范围：12-392天）。只有2名患者（3.8％）出现3级GI毒性，治疗耐受性良好。3个月时AFP反应，放射反应率和疾病控制率分别为48.6％，15.1％和54.5％。一半患者接受姑息性肝放疗后症状症状有所改善，中位反应持续时间为3个月。该治疗耐受性良好，毒性最小。一半患者接受姑息性肝放疗后症状症状有所改善，中位反应持续时间为3个月。该治疗耐受性良好，毒性最小。一半患者接受姑息性肝放疗后症状症状有所改善，中位反应持续时间为3个月。该治疗耐受性良好，毒性最小。
京公网安备 11010802027423号